Bromazepam
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Bromazepam: GABA-A positive allosteric modulator (benzodiazepine) → migraine disorder
One-Sentence Summary
Bromazepam is a benzodiazepine that acts on GABA-A receptors and is marketed in Australia as an oral tablet. The TxGNN model predicts it may be relevant to migraine disorder, but there are currently no clinical trials and no publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | migraine disorder |
| TxGNN Prediction Score | 0.9906 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Bromazepam belongs to the benzodiazepine class, which enhances GABA-A receptor signalling and dampens central nervous system excitability.
A possible, unproven link to migraine is that reduced central hyperexcitability or lower muscle tension could modify some headache triggers. No trials or literature were found to support this. Benzodiazepines are not an established migraine therapy, and they carry risks of dependence and medication-overuse headache. The prediction should be treated as a hypothesis only.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 4150K | Lexotan | Tablet 3 mg | Not recorded in the local data |
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
No drug interaction records were found in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score (0.9906), with no clinical trials or publications addressing migraine disorder. Benzodiazepines carry dependence and medication-overuse headache concerns, so there is no basis to advance.
To proceed, the following is needed:
- Clinical or observational studies that directly examine bromazepam in migraine disorder
- Detailed mechanism of action data and a clearer mechanistic rationale
- Review of the TGA-approved Product Information for warnings and contraindications
- A risk assessment covering dependence and medication-overuse headache
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.